kabutan

AnGes, Inc.(4563) Summary

4563
TSE Growth
AnGes, Inc.
51
JPY
-1
(-1.92%)
Apr 30, 9:33 am JST
0.31
USD
Apr 29, 8:33 pm EDT
Result
PTS
outside of trading hours
51.6
Apr 30, 9:37 am JST
Summary Chart Historical News Financial Result
PER
PBR
6.77
Yield
ー%
Margin Trading Ratio
8.26
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
52 JPY 0.32 USD
Previous Close Apr 28
52 JPY 0.32 USD
High Apr 30, 9:00 am
52 JPY 0.32 USD
Low Apr 30, 9:00 am
51 JPY 0.31 USD
Volume
440,100
Trading Value
0.02B JPY 0.14M USD
VWAP
51.88 JPY 0.32 USD
Minimum Trading Value
5,100 JPY 31 USD
Market Cap
0.02T JPY 0.13B USD
Number of Trades
24
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
572
1-Year High Aug 12, 2025
5,987
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 1,391,600 23,792,400 17.10
Apr 17, 2026 1,391,600 23,353,600 16.78
Apr 10, 2026 1,426,700 23,654,900 16.58
Apr 3, 2026 1,417,800 23,903,200 16.86
Mar 27, 2026 1,417,800 24,240,300 17.10
Company Profile
AnGes, Inc. is a biotech venture founded by an Osaka University professor, developing gene therapies and other pharmaceuticals. The company also sells treatments for intractable diseases.
Sector
Pharmaceuticals
AnGes, Inc. is a biotech venture originating from Osaka University Medical School, focusing on the development and sale of pharmaceuticals, particularly gene therapies. The company also provides contract testing services, primarily for rare genetic disease screening. Its subsidiary, EmendoBio Inc., possesses advanced genome editing technologies and is engaged in research and development of new treatments using genome editing products. In 2019, AnGes obtained conditional and time-limited manufacturing and marketing approval for "Collategene," the world's first plasmid DNA-based gene therapy product. The company has entered into an exclusive sales rights agreement with Mitsubishi Tanabe Pharma Corporation for the Japanese market, and has begun sales, recording product sales revenue.